Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Exact Therapeutics ASFRA:56F -2.04%20 3-1 Month Momentum % is -68.15% as of Aug. 20, 2026. GuruFocus rates FRA:56F with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, Exact Therapeutics AS ranks worse than 93.07% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-20), Exact Therapeutics AS's 3-1 Month Momentum % is -68.15%.
The industry rank for Exact Therapeutics AS's 3-1 Month Momentum % or its related term are showing as below:
FRA:56F's 3-1 Month Momentum % is ranked worse than 93.07% of 1386
companies
in the Biotechnology industry
Industry Median: -5.39
vs FRA:56F: -68.15
Exact Therapeutics AS (FRA:56F) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Exact Therapeutics AS 3-1 Month Momentum % Related Terms
FRA:56F vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Exact Therapeutics AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Therapeutics AS 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Exact Therapeutics AS's 3-1 Month Momentum % falls into.
Exact Therapeutics AS (FRA:56F) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Therapeutics AS (FRA:56F) has a 3-1 Month Momentum % of -68.15% as of Aug. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Exact Therapeutics AS and its competitors. According to the industry distribution chart, Exact Therapeutics AS ranks #1290 out of 1386 companies in the Biotechnology industry, placing it in the top 93.1%.
Is Exact Therapeutics AS's 3-1 Month Momentum % too high?
Exact Therapeutics AS's current 3-1 Month Momentum % is -68.15%. Based on the distribution chart, Exact Therapeutics AS ranks #1290 out of 1386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Exact Therapeutics AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Exact Therapeutics AS's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Exact Therapeutics AS ranks #1290 out of 1386 companies for 3-1 Month Momentum %. This places Exact Therapeutics AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Exact Therapeutics AS and its competitors. Exact Therapeutics AS's current 3-1 Month Momentum % is -68.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exact Therapeutics AS stock overvalued right now?
Exact Therapeutics AS (FRA:56F) has a current 3-1 Month Momentum % of -68.15%. The current 3-1 Month Momentum % is -68.15%. Exact Therapeutics AS's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Exact Therapeutics AS (FRA:56F), the current 3-1 Month Momentum % is -68.15% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
20GF Score
Get the complete analysis for FRA:56F
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:56F has been successfully added to your 
